Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Continuous positive airway pressure (CPAP) therapy is the gold standard treatment for treating obstructive sleep apnea (OSA). However, patient adherence to CPAP therapy remains a critical challenge, with many individuals finding it difficult to maintain consistent use due to discomfort, lack of understanding, or perceived inconvenience. Augmented reality (AR) offers a novel approach to overcoming these barriers by providing interactive real-time guidance to users, potentially enhancing adherence rates.
Objective: This clinical trial aims to examine the feasibility of AR implementation and the effect of AR on improving CPAP adherence in patients with OSA.
Methods: A randomized controlled trial with a parallel assignment will be conducted. Participants will be randomly assigned to either an experimental group receiving AR-guided CPAP therapy or a control group receiving standard care. The study will span 6 months, with assessments at baseline (T0), and with follow-ups at 1 month (T1), 3 months (T2), and 6 months (T3) post intervention. The primary outcome measure is CPAP adherence, defined as using the CPAP device for more than 70% of sleep time, with a minimum of 4 hours per night. Secondary outcomes will evaluate the common adverse effects associated with CPAP therapy, device usability, and time required for CPAP machine use education.
Results: This study is funded by the Ministry of Science and Technology, Taiwan (August 2023 to July 2026) and was registered in August 2024 (ClinicalTrials.gov NCT06520592). Participant recruitment is scheduled to begin in April 2025, and by September 2025, we expect to have enrolled 40 participants (50% of the target sample of 80). Preliminary analyses of CPAP adherence at 1 month and usability data are currently underway. Final data collection is anticipated to be completed by December 2025, with results expected to be published by Fall 2026.
Conclusions: Anticipated findings suggest that AR-guided CPAP therapy may significantly enhance patient adherence by improving mask fitting and providing effective, interactive education. If validated, this innovative approach could pave the way for more personalized technology-driven interventions in OSA management and other chronic conditions requiring long-term therapy adherence.
Trial Registration: ClinicalTrials.gov NCT06520592; https://clinicaltrials.gov/study/NCT06520592.
International Registered Report Identifier (irrid): PRR1-10.2196/69757.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093067 | PMC |
| http://dx.doi.org/10.2196/69757 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Eustachian tube dysfunction in obstructive sleep apnea patients: implications for a multimodal treatment approach. A systematic review.
Sleep Breath
September 2025
School of medicine, Università Campus Bio-Medico di Roma, Rome, Italy.
Introduction: It is well known that Obstructive Sleep Apnea (OSA) is a complex disease characterized by an Upper Airway (UA) collapse during sleep, with potential consequences on ENT districts. Recent evidence suggests a possible association with Eustachian Tube Dysfunction (ETD). However, the potential effects of both surgical and non-surgical therapeutic strategies on ET function remain poorly explored in the current literature.
View Article and Find Full Text PDFEarly (≤ 2 h) Bolus Surfactant Replacement Therapy Versus Standard Care in Term (≥ 37 Weeks) Neonates With Meconium Aspiration Syndrome: An Open-Label Randomized Controlled Trial.
Pediatr Pulmonol
September 2025
Department of Neonatology, Lady Hardinge Medical College and Associated Hospitals, New Delhi, India.
Background: Meconium aspiration syndrome (MAS), a common cause of respiratory failure in late preterm and term neonates, is associated with a high risk of mortality and morbidity. Amongst all the treatment modalities for severe MAS, surfactant administration has a proven role in decreasing progressive respiratory failure.
Methods: The present open-label randomised controlled trial aimed to determine the effect of early (≤ 2 h) bolus surfactant therapy as compared to standard care on the total duration of respiratory support.
Novel hypoglossal stimulation markedly improves airflow and airway collapsibility in OSA.
Chest
September 2025
Flinders Health and Medical Research Institute/Adelaide Institute for Sleep Health, Flinders University, Bedford Park, South Australia, Australia.
Background: Hypoglossal nerve stimulation (HNS) to treat obstructive sleep apnea (OSA) currently requires placement of a cuff or 'saddle' electrode around or adjacent to the hypoglossal nerve(s). Limitations for this therapy include cost, invasiveness, and variable efficacy.
Research Question: Can HNS applied via percutaneous implantation of a linear, multi-pair electrode array restore airflow to airway narrowing and/or obstruction, and improve airway collapsibility in people with OSA?
Study Design And Methods: Participants with OSA undergoing drug induced sleep endoscopy with propofol were instrumented with an epiglottic pressure catheter, nasal mask and pneumotachograph.
Macrophage Migratory Inhibitory Factor May Contribute to the Production of Nitric Oxide in Obstructive Sleep Apnea.
J Sleep Res
September 2025
Department of Otorhinolaryngology-Head and Neck Surgery, Kansai Medical University, Hirakata, Japan.
In obstructive sleep apnea (OSA), repeated airway obstruction alters mucosal inflammation, which increases exhaled nitric oxide (NO) production in the nasal cavity. However, the underlying mechanism remains unclear. Accordingly, we aimed to examine the mechanism underlying NO production in patients with OSA.
View Article and Find Full Text PDFAsthma-OSA overlap syndrome: A distinct endophenotype?
Respir Med
September 2025
Department of Public Health and Infectious Diseases, Pulmonology Unit, Policlinico Umberto I, "Sapienza" University of Rome, 00185, Rome, Italy.
Purpose: Asthma and obstructive sleep apnea (OSA) are two respiratory diseases that often may coexist, resulting in Alternative Overlap Syndrome (aOVS), which is still underestimated and underdiagnosed.
Objectives: This state-of-art review aims to describe the current evidence on aOVS, including its pathophysiology, clinical, functional and therapeutic implications. A secondary objective is to assess whether aOVS can be identified as a distinct endophenotype needing personalized diagnostic and therapeutic strategies.